Home
/
AbbVie Inc.
/
Financials
/
Quarterly
AbbVie Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that AbbVie Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$15.78B
Nov 4, 2025
Q2
2025
Jun 30, 2025
$15.42B
Aug 4, 2025
Q1
2025
Mar 31, 2025
$13.34B
May 9, 2025
Q3
2025
Sep 30, 2024
$14.46B
Nov 4, 2025
Q2
2025
Jun 30, 2024
$14.46B
Aug 4, 2025
Q1
2025
Mar 31, 2024
$12.31B
May 9, 2025
Q3
2024
Sep 30, 2023
$13.93B
Nov 4, 2024
Q2
2024
Jun 30, 2023
$13.87B
Aug 7, 2024
Q1
2024
Mar 31, 2023
$12.23B
May 3, 2024
Q3
2023
Sep 30, 2022
$14.81B
Nov 6, 2023
Q2
2023
Jun 30, 2022
$14.58B
Aug 7, 2023
Q1
2023
Mar 31, 2022
$13.54B
May 5, 2023
Q3
2022
Sep 30, 2021
$14.34B
Nov 4, 2022
Q2
2022
Jun 30, 2021
$13.96B
Aug 4, 2022
Q1
2022
Mar 31, 2021
$13.01B
May 6, 2022
Q3
2021
Sep 30, 2020
$12.90B
Nov 2, 2021
Q2
2021
Jun 30, 2020
$10.43B
Aug 2, 2021
Q1
2021
Mar 31, 2020
$8.62B
May 7, 2021
Q3
2020
Sep 30, 2019
$8.48B
Nov 4, 2020
Q2
2020
Jun 30, 2019
$8.26B
Aug 4, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$8.24B
Nov 7, 2018
Q2
2018
Jun 30, 2018
$8.28B
Aug 7, 2018
Q1
2018
Mar 31, 2018
$7.93B
May 4, 2018
Q3
2018
Sep 30, 2017
$7.00B
Nov 7, 2018
Q2
2018
Jun 30, 2017
$6.94B
Aug 7, 2018
Q1
2018
Mar 31, 2017
$6.54B
May 4, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2015
Mar 31, 2015
$5.04B
May 8, 2015
Q3
2014
Sep 30, 2014
$5.02B
Nov 7, 2014
Q2
2014
Jun 30, 2014
$4.93B
Aug 7, 2014
Q1
2015
Mar 31, 2014
$4.56B
May 8, 2015
Q3
2014
Sep 30, 2013
$4.66B
Nov 7, 2014
Q2
2014
Jun 30, 2013
$4.69B
Aug 7, 2014
Q1
2014
Mar 31, 2013
$4.33B
May 9, 2014
Q3
2013
Sep 30, 2012
$4.51B
Nov 12, 2013
Q2
2013
Jun 30, 2012
$4.49B
Aug 9, 2013
Q1
2013
Mar 31, 2012
$4.17B
May 8, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$186.00M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$938.00M
Aug 4, 2025
Q1
2025
Mar 31, 2025
$1.29B
May 9, 2025
Q3
2025
Sep 30, 2024
$1.56B
Nov 4, 2025
Q2
2025
Jun 30, 2024
$1.37B
Aug 4, 2025
Q1
2025
Mar 31, 2024
$1.37B
May 9, 2025
Q3
2024
Sep 30, 2023
$1.78B
Nov 4, 2024
Q2
2024
Jun 30, 2023
$2.02B
Aug 7, 2024
Q1
2024
Mar 31, 2023
$239.00M
May 3, 2024
Q3
2023
Sep 30, 2022
$3.95B
Nov 6, 2023
Q2
2023
Jun 30, 2022
$924.00M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$4.49B
May 5, 2023
Q3
2022
Sep 30, 2021
$3.18B
Nov 4, 2022
Q2
2022
Jun 30, 2021
$766.00M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$3.55B
May 6, 2022
Q3
2021
Sep 30, 2020
$2.31B
Nov 2, 2021
Q2
2021
Jun 30, 2020
($738.00M)
Aug 2, 2021
Q1
2021
Mar 31, 2020
$3.01B
May 7, 2021
Q3
2020
Sep 30, 2019
$1.88B
Nov 4, 2020
Q2
2020
Jun 30, 2019
$741.00M
Aug 4, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.90B
Nov 4, 2025
Q2
2025
Jun 30, 2025
$4.89B
Aug 4, 2025
Q1
2025
Mar 31, 2025
$3.73B
May 9, 2025
Q3
2025
Sep 30, 2024
$3.83B
Nov 4, 2025
Q2
2025
Jun 30, 2024
$4.00B
Aug 4, 2025
Q1
2025
Mar 31, 2024
$2.80B
May 9, 2025
Q3
2024
Sep 30, 2023
$2.28B
Nov 4, 2024
Q2
2024
Jun 30, 2023
$4.51B
Aug 7, 2024
Q1
2024
Mar 31, 2023
$2.77B
May 3, 2024
Q3
2023
Sep 30, 2022
$4.60B
Nov 6, 2023
Q2
2023
Jun 30, 2022
$3.30B
Aug 7, 2023
Q1
2023
Mar 31, 2022
$4.72B
May 5, 2023
Q3
2022
Sep 30, 2021
$4.31B
Nov 4, 2022
Q2
2022
Jun 30, 2021
$4.44B
Aug 4, 2022
Q1
2022
Mar 31, 2021
$4.10B
May 6, 2022
Q3
2021
Sep 30, 2020
$3.26B
Nov 2, 2021
Q2
2021
Jun 30, 2020
$752.00M
Aug 2, 2021
Q1
2021
Mar 31, 2020
$3.60B
May 7, 2021
Q3
2020
Sep 30, 2019
$2.62B
Nov 4, 2020
Q2
2020
Jun 30, 2019
$3.40B
Aug 4, 2020